About PharmaDossier
Source-cited trade coverage for the biopharma teams working across approval, access, launch, manufacturing, and policy.
PharmaDossier is a static editorial publication for biopharma professionals. The site focuses on the lane identified in the R68/R68b research: coverage and access, biosimilar comparison, payer/formulary friction, FDA interpretation, and the commercial meaning of regulated source documents.
What we cover
We cover FDA approvals, biosimilar and interchangeable products, specialty pharmacy, pricing and access, manufacturing capacity, generic entry, pipeline evidence, and policy changes that affect commercial teams.
Editorial standard
Articles are written from primary sources whenever the claim depends on regulated status: FDA labels, Drugs@FDA, DailyMed, the Purple Book, the Orange Book, CMS materials, ClinicalTrials.gov, Federal Register notices, and peer-reviewed literature. Trade coverage and company materials can add context, but they do not replace the source document.
What we avoid
We do not publish personal medical guidance, coupon arbitrage, investment recommendations, or manufacturer-style product pages. Direct branded head terms are usually owned by manufacturers, Drugs.com, GoodRx, and major medical publishers; PharmaDossier is built for the structured access and comparison layer those pages leave behind.
Founded
Established 2026. Powered by VayoMed.